Black Diamond Therapeutics Expects Cash & Equivalents Of $115.2M As Of March-End To Be Sufficient To Fund Operations Into Q3 Of 2025

Black Diamond Therapeutics Expects Cash & Equivalents Of $115.2M As Of March-End To Be Sufficient To Fund Operations Into Q3 Of 2025

BenzingaMay 9 20:12

Black Diamond Therapeutic Q1 2024 GAAP EPS $(0.35) Beats $(0.44) Estimate

Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.44) by 20.45 percent.

BenzingaMay 9 20:11

Press Release: Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update -- Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024

Dow JonesMay 9 19:30

Black Diamond Theraptcs 1Q Loss/Shr 35c >BDTX

Black Diamond Theraptcs 1Q Loss/Shr 35c >BDTX

Dow JonesMay 9 19:30

Black Diamond Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 19:17 · Announcements

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

PDF Version Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; ini

Black Diamond TherapeuticsMay 9 12:00